# GWAS of extended prescription analgesic use identifies genetic loci in chronic pain.

- **DOI:** [10.1038/s41467-026-71434-8](https://doi.org/10.1038/s41467-026-71434-8)
- **Rating:** Sound (3.4 out of 5)
- **Verdict:** A large two-biobank genetics resource expands analgesic-use association mapping, but the unvalidated prescription proxy limits claims about chronic-pain biology.
- **Framework version:** v5.9
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-10-08
- **Evaluation page:** https://www.nabu.science/paper/10.1038%2Fs41467-026-71434-8

## Key claims

1. Integrating these genetic associations with functional data identifies potential mechanisms involved in chronic pain, implicating oligodendrocyte differentiation, neuronal guidance, endolysosomal function and post-synaptic endosome recycling.
   - Support: Tentative
   - Type: Primary finding
   - Basis: functional enrichments are indirect and inherit uncertainty from the prescription-based phenotype
   - Location: Abstract
2. We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information.
   - Support: Tentative
   - Type: Secondary
   - Basis: known-locus overlap cannot separate pain signal from medication-use and opioid-related determinants
   - Location: Results, Discovery of 140 Genetic Associations
3. The strongest genetic correlations were found between pain duration phenotypes and depression or post-traumatic stress disorder.
   - Support: Supported
   - Type: Secondary
   - Basis: reported LDSC estimates pass the stated multiple-testing threshold, subject to proxy-phenotype interpretation
   - Location: Results, Shared Genetic Architecture of Pain with Neuropsychiatric and Immunological Traits

## Strengths

- **Large two-biobank association resource** The study meta-analyses 11 prescription-derived phenotypes across UK Biobank and FinnGen, with overall sample sizes reaching 692,039 participants.
  - Dimension: contribution
  - Location: Results, Discovery of 140 Genetic Associations; Table 1
- **Broad complementary analytical programme** Common-variant GWAS is supplemented by rare-variant burden tests, colocalisation, TWAS, cell-type analysis, mouse-phenotype enrichment, and genetic-correlation analyses.
  - Dimension: methodological rigour
  - Location: Methods, Overview of Analyses; Figure 6
- **Substantive discussion of study boundaries** The Discussion identifies restrictions arising from European ancestry, UK and Finnish healthcare systems, prescription ascertainment, and use of a UK Biobank LD reference for Finnish data.
  - Dimension: positioning
  - Location: Discussion, limitations paragraphs

## Limitations

- **Prescription proxy lacks direct validation** The phenotype assumes 30-day prescriptions and combines diverse analgesics, while prolonged prescribing can reflect factors other than chronic pain. No direct comparison with diagnosis-based or patient-reported pain in the same cohorts is presented.
  - Dimension: methodological rigour
  - Location: Methods, Phenotype Definitions; Discussion, limitations paragraph
- **Headline counts are inconsistently presented** The Abstract reports 78 novel and 62 previously reported associations, but Table 1 sums to approximately 85 novel and 55 previously reported signals. The total of 140 also aggregates results across 11 overlapping phenotypes rather than representing 140 unique loci.
  - Dimension: contribution
  - Location: Abstract; Table 1; Discussion, paragraph 1
- **Biological interpretations exceed tested contrasts** Sex specificity is inferred from significant-versus-nonsignificant findings without a reported heterogeneity test, and functional enrichments remain hypothesis-generating rather than validated mechanisms.
  - Dimension: reporting
  - Location: Results, Sex-Stratified Analysis and Functional Analysis; Discussion, paragraph 3

## Reliability checks

Caveats (4 of 4 checks).

- **Results check:** Noted
  - We detected many associations at loci previously reported in the literature, demonstrating that our prescription-based definitions of chronic pain are capturing relevant disease information: "including 78 novel (e.g. ARPP21, CNTNAP2) and 62 previously reported (e.g. SLC39A8, DCC, TRPM8) associations." (Abstract) vs "PainChronic painChronic pain patients defined as >90 days prescribed analgesics vs healthy controls (GP linkage and no chronic pain)128,985563,05435,550156,14193,435406,913482820Strong opioid use vs healthyStrong opioids ever prescribed vs healthy controls (GP linkage and no chronic pain)71,837563,05416,505156,14155,223406,913362016Strong opioid > 90 days vs healthyStrong opioids prescribed for more than 90 days vs healthy controls (GP linkage and no chronic pain)31,944563,0548100156,14123,844406,9131587Time on analgesics Q4 vs healthyQuartile 4 of the time on analgesics compared to participants not receiving analgesics32,474563,0549063156,14123,411406,91321129Cessation Time Q4 vs healthyQuartile 4 of the time to stop analgesics compared to participants not receiving analgesics32,412563,0548992156,14123,420406,91313103Pain severityStrong opioid use > 90 days vs neverStrong opioids ever prescribed vs patients with >90 days prescribed analgesics but never prescribed strong opioids31,91557,085807118,98223,84438,103220Strong opioid >90 days vs <90 daysStrong opioids prescribed for more than 90 days vs Strong opioids prescribed for less than 90 days31,91523,6828071529123,84418,391000Pain durationTime on analgesics Q4 vs Q1Quartile 4 of the time on analgesics compared to Quartile 1 of the time on analgesics32,43233,0749021870923,41124,365110Time on analgesics Q4 vs Q1-Q3Quartile 4 of the time on analgesics compared to all others with time on analgesics32,43296,427902126,40323,41170,024220Cessation Time Q4 vs Q1Quartile 4 of the time to stop analgesics compared to Quartile 1 of the time to stop analgesics32,38232,2598962889423,42023,365000Cessation Time Q4 vs Q1-Q3Quartile 4 of the time to stop analgesics compared to all others time to stop analgesics32,38296,477896226,46223,42070,015220" (Table 1, phenotype rows). Summing Table 1's novel-signal counts gives 28+20+8+12+10+2+0+1+2+0+2=85, and summing its previously reported counts gives 20+16+7+9+3=55, preserving the total of 140 and the finding of many previously reported associations. → Conclusion holds
  - Minor reporting notes (1):
    - Descriptive: "The final dataset included 21 million SNP for N = 473,681 individuals." (Methods, Genotyping and imputation, FinnGen) vs "Chronic painChronic pain patients defined as >90 days prescribed analgesics vs healthy controls (GP linkage and no chronic pain)128,985563,05435,550156,14193,435406,913482820" (Table 1, Chronic pain row). The FinnGen chronic-pain row contains 93,435 cases plus 406,913 controls, implying 500,348 participants, which exceeds the stated final dataset of 473,681 by 26,667, but the supplied text does not establish which sample count is erroneous. → Effect on result unclear
- **Reporting and transparency:** Noted. The candidate-gene enumeration contains nine names despite stating seven, and the genetic-correlation reporting gives conflicting Bonferroni test counts. Neither issue establishes a changed association result.
  - Conflict of interest: not stated · Ethics approval: declared · Data availability: declared · Code availability: declared
- **Reference integrity:** Clean. 93 of 93 checkable references verified
  - 97 references in manuscript
  - 4 have no canonical index record — counted, but not index-checkable
  - 5 references confirmed by manual review
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Clean
- **Summary:** No retraction or expression of concern found in Crossref (includes Retraction Watch).
- **Last checked:** 2026-10-17
